首页> 美国政府科技报告 >Purification of Cu-67 and Macrocyclic chelates for targeted therapy. DOE annual report, 1993--94
【24h】

Purification of Cu-67 and Macrocyclic chelates for targeted therapy. DOE annual report, 1993--94

机译:纯化Cu-67和大环螯合物用于靶向治疗。能源部年度报告,1993--94

获取原文

摘要

Cu-67 produced at the Brookhaven Linac Isotope Producer (BLIP) is purified from zinc target material and coproduced radioisotopes of cobalt, chromium, nickel, and gallium by a multi-step extraction process. This procedure introduces applicable amounts of cold copper into the sample, lowering the specific activity of the Cu-67. It is their goal to develop a procedure with which to purify Cu-67 from the other radioisotopes produced, while at the same time minimize the amount of cold copper introduced into the system. There are two different approaches that they devised for the purification of Cu-67. They are an extraction method similar to what is used at Brookhaven already, and a copper affinity column. Bifunctional macrocyclic chelates have been developed to conjugate metals to antibodies, and metal chelated antibodies have been shown to have slower clearance from the tumor than iodinated antibodies. This provides a mechanism for increasing tumor radiation dose and the therapeutic index. Conditions for Cu-67 radiolabeling of TETA immunoconjugates have been optimized, leading to rapid, quantitative complexation of metal binding sites, further contributing to high radioactive yield and to the routine production of Cu-67 radiolabed immunoconjugates of therapeutic quality.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号